Characterization of ceftazidime resistance mechanisms in clinical isolates of Burkholderia pseudomallei from Australia.

PloS One
Derek S SarovichDavid M Wagner

Abstract

Burkholderia pseudomallei is a gram-negative bacterium that causes the serious human disease, melioidosis. There is no vaccine against melioidosis and it can be fatal if not treated with a specific antibiotic regimen, which typically includes the third-generation cephalosporin, ceftazidime (CAZ). There have been several resistance mechanisms described for B. pseudomallei, of which the best described are amino acid changes that alter substrate specificity in the highly conserved class A β-lactamase, PenA. In the current study, we sequenced penA from isolates sequentially derived from two melioidosis patients with wild-type (1.5 µg/mL) and, subsequently, resistant (16 or ≥256 µg/mL) CAZ phenotypes. We identified two single-nucleotide polymorphisms (SNPs) that directly increased CAZ hydrolysis. One SNP caused an amino acid substitution (C69Y) near the active site of PenA, whereas a second novel SNP was found within the penA promoter region. In both instances, the CAZ resistance phenotype corresponded directly with the SNP genotype. Interestingly, these SNPs appeared after infection and under selection from CAZ chemotherapy. Through heterologous cloning and expression, and subsequent allelic exchange in the native bacterium, we con...Continue Reading

References

Oct 1, 1992·Research in Microbiology·X de LamballerieP de Micco
May 15, 1991·The Biochemical Journal·R P AmblerS G Waley
Sep 1, 1987·The Journal of Antimicrobial Chemotherapy·D M LivermoreY K Leung
May 1, 1980·Antimicrobial Agents and Chemotherapy·C H O'CallaghanS M Harding
Jun 1, 1993·Journal of Clinical Microbiology·P M DesmarchelierT L Pitt
Mar 1, 1995·Antimicrobial Agents and Chemotherapy·K V Clemons, D A Stevens
Feb 27, 1999·Antimicrobial Agents and Chemotherapy·R A MooreD E Woods
Sep 7, 2000·Transactions of the Royal Society of Tropical Medicine and Hygiene·B J CurrieS P Jacups
Jul 13, 2004·Trends in Biotechnology·Claes GustafssonJeremy Minshull
Aug 13, 2004·Environmental Microbiology·Esther M GaborDick B Janssen
Sep 21, 2004·Proceedings of the National Academy of Sciences of the United States of America·Matthew T G HoldenJulian Parkhill
Apr 16, 2005·Clinical Microbiology Reviews·Allen C Cheng, Bart J Currie
Dec 8, 2005·Journal of Clinical Microbiology·Bina MaharjanSharon J Peacock
Nov 29, 2008·BMC Genomics·Apichai TuanyokPaul Keim
Jan 16, 2009·Transactions of the Royal Society of Tropical Medicine and Hygiene·Dimitry V ViktorovVladimir V Alekseev
Jul 29, 2009·The American Journal of Tropical Medicine and Hygiene·Direk LimmathurotsakulSharon J Peacock
Sep 18, 2010·Current Opinion in Infectious Diseases·Allen C Cheng
Jul 13, 2011·Frontiers in Microbiology·Drew A RhollHerbert P Schweizer
Oct 19, 2011·Antimicrobial Agents and Chemotherapy·Rebecca J MalottDavid P Speert
Apr 1, 2015·Antimicrobial Agents and Chemotherapy·Amit VikramKyle J Bibby

❮ Previous
Next ❯

Citations

Oct 15, 2014·Expert Review of Anti-infective Therapy·Joshua K StoneMary N Burtnick
Jan 3, 2013·Nephrology·Zulfikar Jabbar, Bart J Currie
Oct 2, 2012·Current Opinion in Microbiology·M E TörökS J Peacock
Mar 13, 2014·International Journal of Antimicrobial Agents·David Dance
Oct 6, 2016·Journal of Medical Microbiology·Nopphasul SirijantSurasakdi Wongratanacheewin
Jul 20, 2018·Microbiology·Katherine A RhodesHerbert P Schweizer
Apr 12, 2017·Antimicrobial Agents and Chemotherapy·Julia V BugryshevaLinda M Weigel
Dec 30, 2015·Antimicrobial Agents and Chemotherapy·Linnell B RandallHerbert P Schweizer
Sep 15, 2017·PLoS Neglected Tropical Diseases·Erin P PriceDavid M Wagner
Feb 3, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Derek S SarovichErin P Price
Sep 25, 2019·Antimicrobial Agents and Chemotherapy·Jeffry D ShearerKelly L Warfield
Mar 13, 2020·Clinical Microbiology Reviews·I GassiepR Norton
Jul 22, 2017·BMC Research Notes·Subarna DuttaJalaluddin Ashraful Haq
Jul 18, 2018·Frontiers in Cellular and Infection Microbiology·Brittany N RossAlfredo G Torres
May 9, 2012·Antimicrobial Agents and Chemotherapy·Hyojeong YiHeenam Stanley Kim
Jan 1, 2014·ACS Medicinal Chemistry Letters·Phumvadee WangtrakuldeeTimothy J Hagen

❮ Previous
Next ❯

Datasets Mentioned

BETA
JQ364927
JQ364935

Methods Mentioned

BETA
PCR
PCRs
genotyping
protein folding

Software Mentioned

Select

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Carcinoma, Bronchogenic

Bronchogenic Carcinoma is a malignant lung cancer arising in the epithelium of the bronchus or bronchiole. Discover the latest research on Bronchogenic Carcinoma here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.